SCHEMBL7624331

SCHEMBL7624331

COc1ccc2c(c1)C(c1ccccc1)CN(C(=O)n1ccnc1)CC2

nearest known ligand 0.51

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ SLC6A2 P23975 2/20 0.51
▸ SLC6A4 P31645 2/20 0.51
▸ SLC6A3 Q01959 2/20 0.51
▸ TAS2R14 Q9NYV8 1/20 0.43
▸ FAAH O00519 4/20 0.43
▸ MGLL Q99685 3/20 0.43
▸ MTNR1A P48039 1/20 0.41
▸ MTNR1B P49286 1/20 0.41
▸ DRD1 P21728 5/20 0.41
▸ HTR2A P28223 1/20 0.41
▸ CYP3A4 P08684 1/20 0.41
▸ CYP2D6 P10635 1/20 0.41
▸ KDM4E B2RXH2 1/20 0.40
▸ ALDH1A1 P00352 1/20 0.40
▸ LMNA P02545 1/20 0.40
▸ MAPT P10636 1/20 0.40
▸ TSHR P16473 1/20 0.40
▸ L3MBTL1 Q9Y468 1/20 0.40
▸ ADAM17 P78536 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7626298 0.88 CYP3A4 (0.56) FAAHMGLLCYP3A4CYP2D6ALDH1A1
SCHEMBL7626253 0.85 ALDH1A1 (0.53) SLC6A2SLC6A4SLC6A3FAAHMGLL
SCHEMBL7625264 0.83 DRD1 (0.54) DRD1CYP3A4CYP2D6KDM4ELMNA
SCHEMBL10345414 0.82 SLC6A2 (0.58) SLC6A2SLC6A4SLC6A3TAS2R14MTNR1A
SCHEMBL7626328 0.81 CYP2D6 (0.44) FAAHMGLLDRD1CYP3A4CYP2D6
SCHEMBL18085044 0.78 SLC6A2 (0.54) SLC6A2SLC6A4SLC6A3TAS2R14MTNR1A
SCHEMBL18085053 0.78 SLC6A2 (0.54) SLC6A2SLC6A4SLC6A3TAS2R14MTNR1A
SCHEMBL7621265 0.76 CYP3A4 (0.56) DRD1CYP3A4CYP2D6KDM4EALDH1A1
SCHEMBL18085059 0.73 SLC6A2 (0.76) SLC6A2SLC6A4SLC6A3DRD1HTR2A
SCHEMBL11393016 0.73 SLC6A2 (0.76) SLC6A2SLC6A4SLC6A3DRD1HTR2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20020019389-A1 Urea derivative useful as an anti-cancer agent and process for preparing same CHACONNE NSI CO., LTD. (KR) 2002-02-14 — — US claimed
WO-2001095856-A2 UREA DERIVATIVE USEFUL AS AN ANTI-CANCER AGENT AND PROCESS FOR PREPARING SAME CHACONNE NSI CO., LTD. (KR) 2001-12-20 — — WO claimed
US-20020019389-A1 Urea derivative useful as an anti-cancer agent and process for preparing same CHACONNE NSI CO., LTD. (KR) 2002-02-14 — — US disclosed
WO-2001095856-A2 UREA DERIVATIVE USEFUL AS AN ANTI-CANCER AGENT AND PROCESS FOR PREPARING SAME CHACONNE NSI CO., LTD. (KR) 2001-12-20 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020019389-A1 Urea derivative useful as an anti-cancer agent and process for preparing same UTS2R, SLC14A1, URB2 SLC6A2 4597/4885SLC6A4 4652/4885SLC6A3 4772/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback